FOLR1 and peritoneum cancer: Recently, 2 clinical trials reported the safety and efficacy of the combination of mirvetuximab soravtansine and bevacizumab in patients with PRrOC, showing improved overall response rates.[49,50] Consequently, the Food and Drug Administration approved its use in adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers on November 14, 2022.